Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas

✍ Scribed by John W. Greiner; Richard V. Smalley; Ernest C. Borden; Edward W. Martin JR.; Fiorella Guadagni; Mario Roselli; Jeffrey Schlom

• Publisher: John Wiley and Sons
• Year: 1991
• Tongue: English
• Weight: 456 KB
• Volume: 48
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930480504

✦ Synopsis

Monoclonal antibodies (MAbs) which recognize a human tumor antigen, termed tumor-associated glycoprotein-72 (TAG-72), have successfully been used to localize primary as well as metastatic colorectal tumor lesions in patients. The localization of the anti-TAG-72 MAbs has also been exploited intraoperatively using a hand-held gamma probe. That procedure, termed radioimmunoguided surgery (RIGS), has identified occult tumors which were not detected using standard external imaging techniques. In another clinical trial, interferon-gamma (IFN-gamma) was administered intraperitoneally to patients diagnosed with either gastrointestinal or ovarian carcinoma with secondary ascites. Analysis of the tumor cells isolated from the malignant ascites revealed a substantial increase in TAG-72 expression on the surface of tumor cells isolated from seven of eight patients. The results provide evidence that the combination of an anti-carcinoma MAb with the administration of a cytokine, such as IFN-gamma, may be an effective approach for the detection and subsequent treatment, of colorectal carcinoma.